Ignite Creation Date:
2025-12-24 @ 11:08 PM
Ignite Modification Date:
2026-01-04 @ 2:53 AM
Study NCT ID:
NCT04164069
Status:
COMPLETED
Last Update Posted:
2024-12-27
First Post:
2019-10-11
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab
Sponsor:
Anne Noonan
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-09-02
Start Date Type:
ACTUAL
Primary Completion Date:
2023-06-22
Primary Completion Date Type:
ACTUAL
Completion Date:
2023-06-22
Completion Date Type:
ACTUAL
First Submit Date:
2019-10-11
First Submit QC Date:
None
Study First Post Date:
2019-11-15
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-12-21
Last Update Post Date:
2024-12-27
Last Update Post Date Type:
ACTUAL